Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Department of Urology, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
Aging (Albany NY). 2024 Feb 14;16(4):3647-3673. doi: 10.18632/aging.205550.
Disulfidptosis, a form of cell death induced by abnormal intracellular accumulation of disulfides, is a newly recognized variety of cell death. Clear cell renal cell carcinoma (ccRCC) is a usual urological tumor that poses serious health risks. There are few studies of disulfidptosis-related genes (DRGs) in ccRCC so far.
The expression, transcriptional variants, and prognostic role of DRGs were assessed. Based on DRGs, consensus unsupervised clustering analysis was performed to stratify ccRCC patients into various subtypes and constructed a DRG risk scoring model. Patients were stratified into high or low-risk groups by this model. We focused on assessing the discrepancy in prognosis, TME, chemotherapeutic susceptibility, and landscape of immune between the two risk groups. Finally, we validated the expression and explored the biological function of the risk scoring gene FLRT3 through experiments.
The different subtypes had significantly different gene expression, immune, and prognostic landscapes. In the two risk groups, the high-risk group had higher TME scores, more significant immune cell infiltration, and a higher probability of benefiting from immunotherapy, but had a worse prognosis. There were also remarkable differences in chemotherapeutic susceptibility between the two risk groups. In ccRCC cells, the expression of FLRT3 was shown to be lower and its overexpression caused a decrease in cell proliferation and metastatic capacity.
Starting from disulfidptosis, we established a new risk scoring model which can provide new ideas for doctors to forecast patient survival and determine clinical treatment plans.
二硫键过氧化物酶病是一种由细胞内二硫键异常积累诱导的细胞死亡形式,是一种新发现的细胞死亡方式。透明细胞肾细胞癌(ccRCC)是一种常见的泌尿外科肿瘤,对健康构成严重威胁。目前关于 ccRCC 中二硫键过氧化物酶病相关基因(DRGs)的研究较少。
评估了 DRGs 的表达、转录变体和预后作用。基于 DRGs,进行了共识无监督聚类分析,将 ccRCC 患者分为不同的亚型,并构建了 DRG 风险评分模型。根据该模型将患者分为高风险或低风险组。我们重点评估了两组患者在预后、TME、化疗敏感性和免疫景观方面的差异。最后,通过实验验证了风险评分基因 FLRT3 的表达并探索了其生物学功能。
不同亚型的基因表达、免疫和预后景观存在显著差异。在两个风险组中,高风险组的 TME 评分更高,免疫细胞浸润更显著,受益于免疫治疗的可能性更高,但预后更差。两个风险组的化疗敏感性也存在显著差异。在 ccRCC 细胞中,FLRT3 的表达较低,其过表达导致细胞增殖和转移能力下降。
从二硫键过氧化物酶病出发,我们建立了一个新的风险评分模型,可为医生预测患者的生存和确定临床治疗方案提供新的思路。